To ensure that expenses relating to the acquisition or use of devices for use in the detection of fentanyl, xylazine, and other emerging adulterant substances, including test strips, are allowable expenses under certain grant programs.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To ensure that expenses relating to the acquisition or use of devices for use in the detection of fentanyl, xylazine, and other emerging adulterant substances, including test strips, are allowable expenses under certain grant programs., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Immigration, Criminal Justice.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HD230CF8AC5014D82A0393E3B6AAA7FEB: 1. Short title This Act may be cited as the Preventing Overdoses with Test Strips Act.
- Section HD8DAEA0B05F64B33A00C4E98F516F8CF: 2. Amending the 21st Century Cures Act to authorize the use of funds for devices for use in the detection of fentanyl, xylazine, and other emerging adulterant...
- Section HE0375B8D43B64676AE4EF7EBEB23ADF6: 3. Amending the Public Health Service Act to authorize the use of funds for devices for use in the detection of fentanyl, xylazine, and other emerging...
- Section H6F2DD707F5D247439F0DFB50D976DEBA: 506B. Use of funds for devices for use in the detection of fentanyl, xylazine, and other emerging adulterant substances Expenses relating to the acquisition or...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To ensure that expenses relating to the acquisition or use of devices for use in the detection of fentanyl, xylazine, and other emerging adulterant substances, including test strips, are allowable expenses under certain grant programs., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Immigration, Criminal Justice
Primary Purpose
This bill, To ensure that expenses relating to the acquisition or use of devices for use in the detection of fentanyl, xylazine, and other emerging adulterant substances, including test strips, are allowable expenses under certain grant programs., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Gottheimer (for himself, Mr. Bacon, and Mr. Gallego) introduced …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "federal_implementing_agencies"
- → Federal agencies assigned duties by the bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology